CD30 CAR-T Cell Treatment for Early-Stage Hodgkin Lymphoma Relapse
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immunotherapy called CAR-T cells—specially engineered immune cells designed to target and destroy Hodgkin lymphoma that has come back after initial treatment. It's designed for patients with low-risk disease who respond well to re-induction (initial salvage) therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 29 years old
- You must have confirmed CD30-positive classical Hodgkin lymphoma that has relapsed (come back after treatment)
- Your disease must meet 'low-risk' criteria based on stage at diagnosis, time since end of prior therapy, and absence of B symptoms or spread outside lymph nodes
- You must be able to undergo re-induction therapy and show a good response to it before receiving CAR-T cells
- You must be in generally good health (Karnofsky score ≥60%, meaning you can carry out most daily activities)
- If you can have children, you must use two forms of contraception for 6 months after treatment; if you're male with a female partner, you must use contraception for 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (T-cells) that are specially designed to attack a protein called CD30 found on Hodgkin lymphoma cells. It's given after a stem cell transplant to try to prevent the cancer from coming back in people with high-risk disease.
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
This trial tests a new type of CAR-T cell therapy that targets both CD20 and CD30 proteins on lymphoma cells. It is for people whose lymphoma has returned or not responded after multiple treatments, including stem cell transplant.
This trial tests a new type of immunotherapy called CD30 CAR-T cells for people with CD30-positive lymphoma that has come back or hasn't responded to other treatments. The treatment uses your own immune cells that are specially trained to find and kill lymphoma cells carrying the CD30 marker.
This trial tests a new CAR-T cell therapy that targets two proteins (CD20 and CD30) on lymphoma cells. It is for people whose lymphoma has come back or not responded to other treatments, including previous stem cell transplants. The goal is to see if this treatment is safe and helps shrink or control the lymphoma.
This trial tests a new treatment called CD30 CAR-T, which uses your own immune cells to attack lymphoma cells that have the CD30 protein. It is for people whose lymphoma has come back or not responded to at least 2 prior treatments.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.